当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Adequate SIRT activity dose is as important as adequate chemotherapy dose
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-11-01 , DOI: 10.1016/s1470-2045(17)30811-2
Arthur J A T Braat , S Cheenu Kappadath , Rutger C G Bruijnen , Andor F van den Hoven , Armeen Mahvash , Hugo W A M de Jong , Marnix G E H Lam

In their Article, Harpreet Wasan and colleagues1 reported a combined analysis of three prospective randomised controlled trials (SIRFLOX, FOXFIRE, and FOXFIRE-Global) that compared a regimen of first-line leucovorin, fluorouracil, and oxaliplatin (FOLFOX) plus selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres with FOLFOX alone in patients with colorectal cancer with liver metastases. They found no survival benefit for the FOLFOX plus SIRT group (median overall survival 22·6 months [95% CI 21·0–24·5] with FOLFOX plus SIRT vs 23·3 months [21·8–24·7] with FOLFOX alone; p=0·61).

中文翻译:

足够的SIRT活性剂量与足够的化疗剂量同等重要

Harpreet Wasan及其同事1在其文章中报告了三项前瞻性随机对照试验(SIRFLOX,FOXFIRE和FOXFIRE-Global)的组合分析,该试验比较了一线亚叶酸,氟尿嘧啶和奥沙利铂(FOLFOX)方案与选择性内部放射疗法的方案(SIRT)单独使用FOLFOX的Yttrium-90树脂微球治疗患有肝转移的大肠癌患者。他们发现对FOLFOX加SIRT组没有存活益处(中位总体存活22·6个月[95%CI 21·0-24·5]与FOLFOX加SIRT VS 23·3个月[21·8-24·7]与单独使用FOLFOX; p = 0·61)。
更新日期:2017-11-01
down
wechat
bug